Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors, including Pancreatic Cancer
Summary
The purpose of this phase I/II study is to evaluate the safety and feasibility of CM24 in combination with nivolumab and either gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV in patients with pancreatic cancer.
General Information
NCT#: NCT04731467
Study ID: FW-2020-1
Trial Phase: Phase I/II
Trial Sponsor: Famewave Ltd.
Therapies Used in This Trial: Nab-paclitaxel, Fluorouracil, Gemcitabine, irinotecan liposome injection, Nivolumab, CM-24